Table 3

Clinicopathologic comparisons between EML4–ALK fusion-positive and fusion-negative lung adenocarcinomas
Overall EML4–ALK(+) EML4–ALK(−)
n = 287 n = 37 (%) n = 250 (%) P value
Age Mean ± SD 48.16 ± 11.529 58.17 ± 10.03 <0.001
Median 48 58
Range 24-70 25-81
Sex Male 20(13.1) 133(86.9) 0.999
Female 17(13.1) 113(86.9)
Nonavailable 0 4
Smoking Never smoker 22(13.8) 138(86.2) 0.239
Ever smoker 9(8.9) 92(91.1)
Nonavailable 6 20
Tumor size(mm) Mean ± SD 38.42 ± 24.263 37.59 ± 16.837 0.872
Median 32.50 35.00
Range 7-100 10-90
pT status pT1 4(13.8) 25(86.2) 0.350
pT2 14(8.3) 154(91.7)
pT3-T4 5(15.6) 27(84.4)
Nonavailable 14 44
pN status pN0 2(2.0) 100(98.0) 0.002
pN1 11(16.7) 55(83.3)
pN2-3 7(13.5) 45(86.5)
Nonavailable 17 50
pTNM stages pStage I 2(2.5) 79(97.5) 0.028
pStage II 9(12.2) 65(87.8)
pStage III 9(14.3) 54(85.7)
Nonavailable 17 52

Shan et al.

Shan et al. Diagnostic Pathology 2014 9:3   doi:10.1186/1746-1596-9-3

Open Data